Screener
Alamar Biosciences ALMR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 13,017 | 8,302 |
| Selling, general and administrative | 13,787 | 6,640 |
| Total operating expenses | 26,804 | 14,942 |
| Loss from operations | (12,347) | (8,553) |
| Interest income, net | 539 | 786 |
| Interest expense | (223) | (46) |
| Loss on remeasurement of convertible notes | (8,594) | — |
| Other (expense) income, net | (236) | 154 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's operating income?
- Alamar Biosciences (ALMR) reported operating income of -$12.35M in Q1 2026.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Alamar Biosciences's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude